Related Experiment Videos
Vasoactive intestinal peptide and helodermin inhibit phospholipase A2 activity in vitro
Regulatory Peptides
|November 3, 1993
Summary
Vasoactive intestinal peptide (VIP) and helodermin inhibit phospholipase A2 (PLA2) enzyme activity in vitro. This inhibition may explain their anti-inflammatory effects in lung injury by reducing arachidonic acid release.
Area of Science:
- Biochemistry
- Pharmacology
- Immunology
Background:
- Vasoactive intestinal peptide (VIP) is a neuropeptide known to reduce inflammatory lung injury.
- VIP also inhibits cyclo-oxygenase and lipoxygenase pathways involved in inflammation.
Purpose of the Study:
- To investigate if VIP inhibits phospholipase A2 (PLA2) activity.
- To determine if VIP's anti-inflammatory effects are mediated by reduced arachidonic acid release.
Main Methods:
- Assessed PLA2 activity using radiolabeled E. coli phospholipids.
- Measured the release of free [3H]oleic acid as an indicator of PLA2 activity.
- Tested VIP, helodermin, secretin, and peptide histidine isoleucineamide for PLA2 inhibition.
Main Results:
- VIP dose-dependently inhibited PLA2 from porcine pancreas and Naja naja venom.
- Helodermin also inhibited PLA2, while secretin and peptide histidine isoleucineamide showed minimal effects.
- VIP's potency was comparable to mepacrine, a known PLA2 inhibitor.
Conclusions:
- VIP and helodermin selectively inhibit PLA2 in vitro.
- This PLA2 inhibitory activity may contribute to the observed anti-inflammatory effects of VIP and helodermin in vivo.